香港股市 已收市

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
7.15+0.11 (+1.56%)
收市:04:00PM EDT
7.12 -0.03 (-0.42%)
收市後: 07:39PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價7.04
開市7.13
買盤7.16 x 200
賣出價7.18 x 500
今日波幅7.00 - 7.23
52 週波幅4.03 - 7.95
成交量2,348,482
平均成交量3,660,512
市值1.476B
Beta 值 (5 年,每月)1.88
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.07
業績公佈日2024年8月01日 - 2024年8月05日
遠期股息及收益率無 (無)
除息日
1 年預測目標價14.00
  • Insider Monkey

    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript

    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]

  • Motley Fool

    Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday

    A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.

  • Benzinga

    BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance

    Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g